CCR5-001 / Cidara Therap - LARVOL DELTA

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) - "First-in-class CCR5-targeting DFC, CCR5-001, demonstrated potent CCR5 binding and functional inhibition of CCR5 signaling in cell-based assays. The candidate also demonstrated robust efficacy as a monotherapy in a syngeneic colorectal cancer mouse model, representing a potential to target CCR5 with DFCs in solid cancers where pathology is driven by the CCR5/CCL5 axis."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) - "Later this year, Cidara expects...preclinical data for its oncology DFCs directed against solid tumors."

Preclinical • Oncology • Solid Tumor